Marcin Imielinski, MD, PhD Joins the New York Genome Center as Core Member, Assistant Investigator
The New York Genome Center (NYGC) welcomes Marcin Imielinski, MD, PhD, as a Core Member, Assistant Investigator, where he will develop computational algorithms and apply cutting-edge sequencing technologies to study cancer genome structure. His group will work closely with both the NYGC Bioinformatics team and the Innovation Lab to push forward novel approaches for detecting and analyzing alterations in cancer DNA.
“Next-generation sequencing has revealed unprecedented complexity in cancer genomes,” said Dr Imielinski. “Using computational intuition and large-scale data analysis, we can distill this complexity into biological insights and clinically actionable signals.“
Dr. Imielinski, recipient of a 2014 Burroughs-Wellcome Career Award in Medical Sciences, has authored over 40 publications on topics ranging from systems biology to human genetics to cancer genomics. Additionally, he has contributed to the development of open-source software tools for cancer genome analysis.
“Marcin Imielinski’s expertise in understanding genomic variation and tumor evolution and driving this to help sick patients will be a key tool and resource for the New York Genome Center,” said Robert B. Darnell, NYGC’s President, CEO and Scientific Director. “His collaborative efforts will drive the NYGC forward, and we are delighted to welcome him on board.“
Dr. Imielinski is a Board-certified M.D. pathologist and a PhD computational biologist. He obtained his BS in computer science from Rutgers University and his MD & PhD from University of Pennsylvania School of Medicine.
His primary interests are in cancer genomics, molecular diagnostics, and big-data driven medicine. He will be focusing on how to apply next-generation sequencing and novel computational algorithms to understand complex DNA rearrangements in solid tumors.
Dr. Imielinski will also spend time as an Assistant Professor of Pathology and Computational Genomics in the Meyer Cancer Center at Weill-Cornell Medical College (WCMC), in conjunction with his association at NYGC. At WCMC, he will be part of the Institute for Precision Medicine, where he will help apply NGS cancer diagnostic panels to the stratification and treatment of cancer patients at New York-Presbyterian hospital.
About the New York Genome Center
The New York Genome Center (NYGC) is an independent, nonprofit at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations and partners are united in this unprecedented collaboration of technology, science, and medicine. We harness the power of innovation and discoveries to improve people’s lives – ethically, equitably, and urgently. Member institutions include: Albert Einstein College of Medicine, American Museum of Natural History, Cold Spring Harbor Laboratory, Columbia University College of Physicians and Surgeons, Cornell University/Weill Cornell Medical College, Hospital for Special Surgery, The Jackson Laboratory, Memorial Sloan- Kettering Cancer Center, Icahn School of Medicine at Mount Sinai, NewYork-Presbyterian Hospital, The New York Stem Cell Foundation, New York University, North Shore-LIJ, The Rockefeller University, Roswell Park Cancer Institute and Stony Brook University. For more information, visit: www.nygenome.org.